-
Mashup Score: 5
The ongoing ARASTEP trial evaluates darolutamide plus ADT vs placebo for high-risk prostate cancer biochemical recurrence with PSMA PET-CT-positive lesions, aiming to improve rPFS.
Source: www.targetedonc.comCategories: General Medicine NewsTweet
-
Mashup Score: 2
The ongoing ARASTEP trial evaluates darolutamide plus ADT vs placebo for high-risk prostate cancer biochemical recurrence with PSMA PET-CT-positive lesions, aiming to improve rPFS.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
ARASTEP is actively recruiting and plans to assess the use of darolutamide + ADT for the treatment of high-risk biochemical recurrence of prostate cancer. #pcsm #ASCO25 | @CaPsurvivorship https://t.co/PhODdPVl0w
-
-
Mashup Score: 1
Niraparib plus abiraterone acetate and prednisone significantly reduced the risk of symptomatic progression in patients with BRCA-mutated metastatic castration-sensitive prostate cancer.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Niraparib plus abiraterone acetate and prednisone significantly reduced the risk of symptomatic progression in patients with BRCA-mutated metastatic castration-sensitive prostate cancer. #pcsm #ASCO25 | @ASCO https://t.co/digJIfxxn9
-
ARASTEP is actively recruiting and plans to assess the use of darolutamide + ADT for the treatment of high-risk biochemical recurrence of prostate cancer. #pcsm #ASCO25 | @DanaFarber @CaPsurvivorship Learn more: https://t.co/v6sfp74eCT